Correction to Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: a retrospective analysis of the CLEOPATRA study (The Lancet Oncology (2017) 18(1) (52–62)(S1470204516306313)(10.1016/S1470-2045(16)30631-3));Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: a retrospective analysis of the CLEOPATRA study

The Lancet Oncology

Volumn 18, Issue 1, 2017, Pages 52-62

  Luen, Stephen J ^a   Salgado, Roberto ^b,c   Fox, Stephen ^a   Savas, Peter ^a   Eng Wong, Jennifer ^d   Clark, Emma ^e   Kiermaier, Astrid ^f   Swain, Sandra M ^g   Baselga, Jose ^h   Michiels, Stefan ⁱ   Loi, Sherene ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b GZA Hospitals   (Belgium)

^c JULES BORDET INSTITUTE   (Belgium)

^d GENENTECH INC   (United States)

^e ROCHE PRODUCTS LTD   (United Kingdom)

^f F HOFFMANN LA ROCHE LTD   (Switzerland)

^g GEORGETOWN UNIVERSITY   (United States)

^h MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

ⁱ CENTRE FOR RESEARCH IN EPIDEMIOLOGY AND POPULATION HEALTH   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DOCETAXEL; PERTUZUMAB; PLACEBO; TRASTUZUMAB; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MONOCLONAL ANTIBODY; TAXOID; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; FOLLOW UP; HUMAN; HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 POSITIVE BREAST CANCER; HUMAN TISSUE; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; METASTATIC BREAST CANCER; MULTICENTER STUDY (TOPIC); MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; TUMOR ASSOCIATED LEUKOCYTE; ADOLESCENT; BREAST NEOPLASMS; CANCER STAGING; CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; IMMUNOLOGY; LYMPH NODE METASTASIS; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; PHASE 3 CLINICAL TRIAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE; TUMOR INVASION; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOMARKERS, TUMOR; BREAST NEOPLASMS; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; LYMPHATIC METASTASIS; LYMPHOCYTES, TUMOR-INFILTRATING; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PROGNOSIS; RECEPTOR, ERBB-2; RETROSPECTIVE STUDIES; SURVIVAL RATE; TAXOIDS; TRASTUZUMAB; YOUNG ADULT;

EID: 85007484031     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(18)30850-7     Document Type: Erratum

References (33)

1. 1 Slamon, DJ, Clark, GM, Wong, SG, Levin, WJ, Ullrich, A, McGuire, WL, Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235 (1987), 177–182.
2. 2 Swain, SM, Baselga, J, Kim, SB, et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med 372 (2015), 724–734.
3. 3 Baselga, J, Cortes, J, Im, SA, et al. Biomarker analyses in CLEOPATRA: a phase III, placebo-controlled study of pertuzumab in human epidermal growth factor receptor 2-positive, first-line metastatic breast cancer. J Clin Oncol 32 (2014), 3753–3761.
4. 4 Agus, DB, Akita, RW, Fox, WD, et al. Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell 2 (2002), 127–137.
5. 5 Franklin, MC, Carey, KD, Vajdos, FF, Leahy, DJ, de Vos, AM, Sliwkowski, MX, Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. Cancer Cell 5 (2004), 317–328.
6. 6 Scheuer, W, Friess, T, Burtscher, H, Bossenmaier, B, Endl, J, Hasmann, M, Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models. Cancer Res 69 (2009), 9330–9336.
7. 7 Capelan, M, Pugliano, L, De Azambuja, E, et al. Pertuzumab: new hope for patients with HER2-positive breast cancer. Ann Oncol 24 (2013), 273–282.
8. 8 Denkert, C, von Minckwitz, G, Brase, JC, et al. Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers. J Clin Oncol 33 (2015), 983–991.
9. 9 Salgado, R, Denkert, C, Campbell, C, et al. Tumor-infiltrating lymphocytes and associations with pathological complete response and event-free survival in HER2-positive early-stage breast cancer treated with lapatinib and trastuzumab: a secondary analysis of the NeoALTTO trial. JAMA Oncol 1 (2015), 448–454.
10. 10 Salgado, R, Denkert, C, Demaria, S, et al. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. Ann Oncol 26 (2015), 259–271.
11. 11 Denkert, C, Wienert, S, Poterie, A, et al. Standardized evaluation of tumor-infiltrating lymphocytes in breast cancer: results of the ring studies of the international immuno-oncology biomarker working group. Mod Pathol 29 (2016), 1155–1164.
12. 12 Loi, S, Michiels, S, Salgado, R, et al. Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial. Ann Oncol 25 (2014), 1544–1550.
13. 13 Loi, S, Sirtaine, N, Piette, F, et al. Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02–98. J Clin Oncol 31 (2013), 860–867.
14. 14 Denkert, C, Loibl, S, Noske, A, et al. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol 28 (2010), 105–113.
15. 15 Mittal, D, Gubin, MM, Schreiber, RD, Smyth, MJ, New insights into cancer immunoediting and its three component phases—elimination, equilibrium and escape. Curr Opin Immunol 27 (2014), 16–25.
16. 16 Savas, P, Caramia, F, Teo, ZL, Loi, S, Oncogene addiction and immunity: clinical implications of tumour infiltrating lymphocytes in breast cancers overexpressing the HER2/neu oncogene. Curr Opin Oncol 26 (2014), 562–567.
17. 17 Arnedos, M, Filleron, T, Dieci, MV, et al. Genomic and immune characterization of metastatic breast cancer (MBC): and ancillary studies of the SAFIR01 & M overall survival CATO trials. Ann Oncol, 25(suppl 4), 2014, iv116 (abstr 3510).
18. 18 Tumeh, PC, Rosenblum, M, Handley, N, et al. Abstract 2857: Metastatic site and response to pembrolizumab (anti-PD1 antibody) in melanoma. Cancer Res, 75(15 suppl), 2015 abstr 2857.
19. 19 Svoronos, N, Perales-Puchalt, A, Allegrezza, MJ, et al. Tumor cell-independent estrogen signaling drives disease progression through mobilization of myeloid-derived supressor cells. Cancer Discov, 2016, 10.1158/2159-8290.CD-16-0502 published online Sept 30.
20. 20 Mori, M, Yamada, R, Kobayashi, K, Kawaida, R, Yamamoto, K, Ethnic differences in allele frequency of autoimmune-disease-associated SNPs. J Hum Genet 50 (2005), 264–266.
21. 21 Akinyemiju, T, Moore, JX, Ojesina, AI, Waterbor, JW, Altekruse, SF, Racial disparities in individual breast cancer outcomes by hormone-receptor subtype, area-level socio-economic status and healthcare resources. Breast Cancer Res Treat 157 (2016), 575–586.
22. 22 Michiels, S, Pugliano, L, Marguet, S, et al. Progression-free survival as surrogate end point for overall survival in clinical trials of HER2-targeted agents in HER2-positive metastatic breast cancer. Ann Oncol 27 (2016), 1029–1034.
23. 23 Urruticoechea A, Rizwanullah M, Im S-A, et al. PHEREXA: a phase III study of trastuzumab (H) + capecitabine (X) ± pertuzumab (P) for patients (pts) who progressed during/after one line of H-based therapy in the HER2-positive metastatic breast cancer (MBC) setting. Proc Am Soc Clin Oncol; 34 (suppl): abstr 504.
24. 24 Loi, S, Host antitumor immunity plays a role in the survival of patients with newly diagnosed triple-negative breast cancer. J Clin Oncol 32 (2014), 2935–2937.
25. 25 Borghaei, H, Paz-Ares, L, Horn, L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 373 (2015), 1627–1639.
26. 26 Motzer, RJ, Escudier, B, McDermott, DF, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 373 (2015), 1803–1813.
27. 27 Kroemer, G, Senovilla, L, Galluzzi, L, Andre, F, Zitvogel, L, Natural and therapy-induced immunosurveillance in breast cancer. Nat Med 21 (2015), 1128–1138.
28. 28 Stagg, J, Loi, S, Divisekera, U, et al. Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy. Proc Natl Acad Sci USA 108 (2011), 7142–7147.
29. 29 Park, S, Jiang, Z, Mortenson, ED, et al. The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity. Cancer Cell 18 (2010), 160–170.
30. 30 Garon, EB, Rizvi, NA, Hui, R, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 372 (2015), 2018–2028.
31. 31 Simon, RM, Paik, S, Hayes, DF, Use of archived specimens in evaluation of prognostic and predictive biomarkers. J Natl Cancer Inst 101 (2009), 1446–1452.
32. 32 Adams, S, Gray, RJ, Demaria, S, et al. Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. J Clin Oncol 32 (2014), 2959–2966.
33. 33 Tolaney, SM, Barry, WT, Dang, CT, et al. Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer. N Engl J Med 372 (2015), 134–141.